Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to Lewis heart and skin transplantation models

Transplant Immunology

Volumn 8, Issue 4, 2001, Pages 267-277

  Nikolova, Zariana ^a   Hof, Akiko ^a   Baumlin, Yves ^a   Hof, Robert P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Heterotopic cardiac and tail skin grafting; Immunomodulator; Peripheral lymphocyte count

Indexed keywords

CYCLOSPORIN A; FINGOLIMOD; PLACEBO;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MONOTHERAPY; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RAT; RAT STRAIN; SKIN TRANSPLANTATION; SURVIVAL TIME; WEIGHT GAIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BODY WEIGHT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; MODELS, ANIMAL; PROPYLENE GLYCOLS; RATS; RATS, INBRED LEW; RATS, INBRED STRAINS; SKIN TRANSPLANTATION; SPHINGOSINE;

EID: 0035082902     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(01)00031-4     Document Type: Article

References (25)

1. FTY720: A novel immunosuppressant, induces sequestration of circulating mature lymphocyte by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing
2. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo
3. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation
4. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion and memory
5. A novel immunosuppresant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation
6. FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts
7. The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival
8. Effects of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats
9. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotropic cardiac allografts and synergistic effects in combination with cyclosporine A
10. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine
11. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effects in combination with cyclosporine in rats
12. FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A
13. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival
14. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus
15. FTY720, a new immuno-suppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation
16. Prevention of graft vessel disease by combined FTY720/Cyclosporine A treatment in a rat carotid artery transplantation model
17. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720. Effect of monotherapy and combined treatment with conventional drugs
18. Initial T-cell activation required for transplant vasculopathy in retransplanted rat cardiac allografts
19. Epstein-barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant
20. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients
21. Improved technique of heart transplantation in the rat
22. The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD
23. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group
24. Experimental Graft Arteriosclerosis. I. The Lewis-to-F344 allograft model
25. Safety and pharmacodynamics of multiple doses of FTY720